Plk1-dependent microtubule dynamics promotes androgen receptor signaling in prostate cancer

被引:41
作者
Hou, Xianzeng [1 ,2 ]
Li, Zhiguo [1 ]
Huang, Weize [1 ]
Li, Jiejie [3 ]
Staiger, Christopher [3 ]
Kuang, Shihuan [4 ]
Ratliff, Tim [5 ]
Liu, Xiaoqi [1 ,5 ]
机构
[1] Purdue Univ, Dept Biochem, W Lafayette, IN 47907 USA
[2] Shandong Univ, Prov Hosp, Dept Neurosurg, Jinan 250100, Peoples R China
[3] Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA
[4] Purdue Univ, Dept Anim Sci, W Lafayette, IN 47907 USA
[5] Purdue Univ, Purdue Ctr Canc Res, W Lafayette, IN 47907 USA
关键词
prostate cancer; Plk1; paclitaxel; androgen receptor; microtubule dynamics; POLO-LIKE KINASES; IN-VIVO; APOPTOSIS; CLIP-170; GROWTH; DRUGS; PLK1; POLO-LIKE-KINASE-1; PHOSPHORYLATION; RESISTANCE;
D O I
10.1002/pros.22683
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
BACKGROUND. The androgen receptor (AR) signaling continues to be essential in castrate-resistant prostate cancer (CRPC). Taxel-based chemotherapy is the current standard treatment for CRPC patients. Unfortunately, almost all patients eventually develop resistance toward this chemotherapy. Significantly, it was recently found that the anti-tumor effect of paclitaxel in CRPC is due to its inhibition of AR activity via its inhibition of microtubule dynamics. Polo-like kinase 1 (Plk1), a critical regulator in many cell cycle events, is elevated in prostate cancer (PCa) and linked to tumor grades. Of note, we have previously shown that Plk1 phosphorylates CLIP-170 and p150(Glued), two important regulators of microtubule dynamics. METHODS. We compared paclitaxel-mediated phenotypes (inhibition of the AR signaling, decrease of microtubule dynamics and cell death) of PCa cells expressing different forms of CLIP-170 and p150(Glued) with different Plk1 phosphorylation states. RESULTS. We show that Plk1 phosphorylation of CLIP-170 and p150(Glued) affects cellular responses to paclitaxel. Expression of Plk1-unphosphorylatable mutants of CLIP-170 and p150(Glued) results in increased paclitaxel-induced apoptosis, increased protein degradation of the AR, and decreased nuclear accumulation of the AR in response to androgen in prostate cancer cells. Finally, we show that cells expressing unphosphorylatable mutants of CLIP-170 have defective microtubule dynamics, thus providing a new mechanism to understand how Plk1-associated kinase activity promotes constitutive activation of AR signaling in CRPC. CONCLUSIONS. Our data suggest that a combination of inhibition of Plk1 and paclitaxel might be a novel avenue for treatment of CRPC. Prostate 73: 1352-1363, 2013. (c) 2013 Wiley Periodicals, Inc.
引用
收藏
页码:1352 / 1363
页数:12
相关论文
共 28 条
[1]
Recent Advances in the Development of P-gp Inhibitors [J].
Baumert, Christiane ;
Hilgeroth, Andreas .
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2009, 9 (04) :415-436
[2]
Opinion - The role of apoptosis in cancer development and treatment response [J].
Brown, JM ;
Attardi, LD .
NATURE REVIEWS CANCER, 2005, 5 (03) :231-237
[3]
Apoptosis genes and resistance to cancer therapy - What do the experimental and clinical data tell us? [J].
Brown, M ;
Wilson, G .
CANCER BIOLOGY & THERAPY, 2003, 2 (05) :477-490
[4]
Cory S, 1999, CANCER RES, V59, p1685S
[5]
Taxane-Induced Blockade to Nuclear Accumulation of the Androgen Receptor Predicts Clinical Responses in Metastatic Prostate Cancer [J].
Darshan, Medha S. ;
Loftus, Matthew S. ;
Thadani-Mulero, Maria ;
Levy, Benjamin P. ;
Escuin, Daniel ;
Zhou, Xi Kathy ;
Gjyrezi, Ada ;
Chanel-Vos, Chantal ;
Shen, Ruoqian ;
Tagawa, Scott T. ;
Bander, Neil H. ;
Nanus, David M. ;
Giannakakou, Paraskevi .
CANCER RESEARCH, 2011, 71 (18) :6019-6029
[6]
Polo-like kinases and oncogenesis [J].
Eckerdt, F ;
Yuan, JP ;
Strebhardt, K .
ONCOGENE, 2005, 24 (02) :267-276
[7]
Inhibition of the Androgen Receptor as a Novel Mechanism of Taxol Chemotherapy in Prostate Cancer [J].
Gan, Lu ;
Chen, Shuai ;
Wang, Yuwei ;
Watahiki, Akira ;
Bohrer, Laura ;
Sun, Zhen ;
Wang, Yuzhuo ;
Huang, Haojie .
CANCER RESEARCH, 2009, 69 (21) :8386-8394
[8]
Multidrug resistance in cancer: Role of ATP-dependent transporters [J].
Gottesman, MM ;
Fojo, T ;
Bates, SE .
NATURE REVIEWS CANCER, 2002, 2 (01) :48-58
[9]
Microtubules as a target for anticancer drugs [J].
Jordan, MA ;
Wilson, L .
NATURE REVIEWS CANCER, 2004, 4 (04) :253-265
[10]
Conformational changes in CLIP-170 regulate its binding to microtubules and dynactin localization [J].
Lansbergen, G ;
Komarova, Y ;
Modesti, M ;
Wyman, C ;
Hoogenraad, CC ;
Goodson, HV ;
Lemaitre, RP ;
Drechsel, DN ;
van Munster, E ;
Gadella, TWJ ;
Grosveld, F ;
Galjart, N ;
Borisy, GG ;
Akhmanova, A .
JOURNAL OF CELL BIOLOGY, 2004, 166 (07) :1003-1014